MED12: for The Thyroid Hormone Receptor-Associated Protein Complex 230kDa Component

Target Name: MED12

NCBI ID: G9968

MED12

MED12: for The Thyroid Hormone Receptor-Associated Protein Complex 230kDa Component

MED12: A Potential Drug Target and Biomarker for the Thyroid Hormone Receptor-Associated Protein Complex 230kDa Component

Abstract:

Thyroid hormone plays a crucial role in regulating various physiological processes in the body, including metabolism, growth, and development. The thyroid hormone receptor-associated protein complex (TRAIPC) is a key regulator of thyroid hormone signaling. MED12, a 19 kDa protein component of the TRAIPC, has been identified as a potential drug target and biomarker for several thyroid diseases. In this article, we will discuss the structures and functions of MED12, its potential as a drug target, and its potential as a biomarker for thyroid diseases.

Introduction:

Thyroid hormones are small, structurally diverse proteins that play a critical role in regulating various physiological processes in the body, including metabolism, growth, and development. The thyroid hormone receptor-associated protein complex (TRAIPC) is a key regulator of thyroid hormone signaling. The TRAIPC is a complex of various thyroid hormone receptors (TRAI) and their associated proteins. The TRAIPC plays a crucial role in regulating thyroid hormone signaling by controlling the interactions between TRAI and their associated proteins.

MED12: A 19kDa Protein Component of the TRAIPC

MED12 is a 19 kDa protein component of the TRAIPC. It is located at the N-terminus of TRAIPC and is involved in the regulation of TRAIPC signaling. MED12 is composed of two distinct domains: an N-terminal alpha -helicase domain and a C-terminal T-loop domain. The N-terminal alpha-helicase domain is responsible for the formation of a closed alpha-helicase structure, which is essential for the protein's stability and functions. The C-terminal T-loop domain is involved in the regulation of TRAIPC signaling.

Potential Drug Target:

MED12 has been identified as a potential drug target for several thyroid diseases. Its N-terminus contains a putative N-terminal hypervariable region, which is involved in the regulation of TRAIPC signaling. The N -The terminal variable region contains several potential binding sites, including a putative hormone-binding site and a putative protein-binding site.

MED12 has also been shown to interact with several thyroid hormone receptors, including TRAIPC1 and TRAIPC3. The TRAIPC1 and TRAIPC3 are important regulators of thyroid hormone signaling, and their interaction with MED12 may play a role in the regulation of TRAIPC signaling (10 ).

Biomarker Potential:

MED12 has also been identified as a potential biomarker for several thyroid diseases. Its expression is regulated by various factors, including thyroid hormone signaling. MED12 has been shown to be expressed in thyroid tissue, including the thyroid gland and the parathyroid gland ( 12). It has also been shown to be expressed in various tissues and organs, including the liver, pancreas, and heart.

Conclusion:

MED12 is a 19 kDa protein component of the TRAIPC that has been identified as a potential drug target and biomarker for several thyroid diseases. Its N-terminus contains a putative N-end

Protein Name: Mediator Complex Subunit 12

Functions: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional pre-initiation complex with RNA polymerase II and the general transcription factors. This subunit may specifically regulate transcription of targets of the Wnt signaling pathway and SHH signaling pathway

The "MED12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MED12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets